SRA737 demonstrated favorable safety and efficacy when combined with gemcitabine in preclinical non-small cell lung cancer (NSCLC) and MYC-driven B-cell lymphoma mouse models [36]. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.